Systemic inflammation in gout and the impact of treat-to-target urate-lowering therapy
Gout is characterized by distinct patterns of circulating inflammatory biomarkers and these appear to change over time with treat-to-target ULT to approximate controls. This study supports the importance of treat-to-target ULT in gout management not only for flare prevention, but also to mitigate systemic inflammation.
Authors
- Tony Raymond Merriman (ORCID: https://orcid.org/0000-0003-0844-8726)
- Austin M. Wheeler (ORCID: https://orcid.org/0000-0002-8816-7782)
- Brian D. LaMoreaux (ORCID: https://orcid.org/0000-0001-7521-241X)
- Mary T. Brophy (ORCID: https://orcid.org/0000-0003-2314-4368)
- Michael H. Pillinger (ORCID: https://orcid.org/0000-0003-3168-1542)
- Ryan Ferguson (ORCID: https://orcid.org/0000-0001-8695-5024)
- Ted R. Mikuls (ORCID: https://orcid.org/0000-0002-0897-2272)
- Bryant R. England (ORCID: https://orcid.org/0000-0002-9649-3588)
- Spencer Q. Jones
- Michael J. Duryee (ORCID: https://orcid.org/0000-0001-9104-2238)
- Robert Terkeltaub
- Richard J. Reynolds (ORCID: https://orcid.org/0000-0001-6419-7779)
- James R. O’Dell
- Jeff A. Newcomb
- Tanner J Ourada
Institutions
- Boston University (US)
- Amgen (United States) (US)
- VA NY Harbor Healthcare System (US)
- VA Boston Healthcare System (US)
- University of Alabama at Birmingham (US)
- University of California San Diego (US)
- The Coordinating Center (US)
- VA Nebraska Western Iowa Health Care System (US)
- New York University (US)
- University of Nebraska Medical Center (US)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2025-12-12
- DOI
- https://doi.org/10.1093/rheumatology/keaf680
- Primary Topic
- Gout, Hyperuricemia, Uric Acid
- Type
- article
- Field-Weighted Citation Impact
- 0.00